BIOMAT Database Logo BIOMAT Database Logo

Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors. 2014

Maurizio Taddei, and Elena Cini, and Luca Giannotti, and Giuseppe Giannini, and Gianfranco Battistuzzi, and Davide Vignola, and Loredana Vesci, and Walter Cabri
Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Via A. Moro 2, 53100 Siena, Italy. Electronic address: maurizio.taddei@unisi.it.

A series of SAHA-like molecules were prepared introducing different lactam-carboxyamides in position 7 of the suberoylanilide skeleton. The activity against different HDAC isoforms was tested and the data compared with the corresponding linear products, without substituent in position 7. In general, this modification provided an effective reinforcement of in vitro activity. While the lactam size or the CO/NH group orientation did not strongly influence the inhibition, the contemporary modification of the suberoylamide fragment gave vary active variants in the lactam series, with compound 28 (ST8078AA1) that showed IC50 values between 2 and 10nM against all Class I HDAC isoforms, demonstrating it to be a large spectrum pan-inhibitor. This strong affinity with HDAC was also confirmed by the value of IC50=0.5μM against H460 cells, ranking 28 as one of the most potent HDAC inhibitors described so far.

UI MeSH Term Description Entries
D007769 Lactams Cyclic AMIDES formed from aminocarboxylic acids by the elimination of water. Lactims are the enol forms of lactams. Lactam,Lactim,Lactims
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006655 Histone Deacetylases Deacetylases that remove N-acetyl groups from amino side chains of the amino acids of HISTONES. The enzyme family can be divided into at least three structurally-defined subclasses. Class I and class II deacetylases utilize a zinc-dependent mechanism. The sirtuin histone deacetylases belong to class III and are NAD-dependent enzymes. Class I Histone Deacetylases,Class II Histone Deacetylases,HDAC Proteins,Histone Deacetylase,Histone Deacetylase Complexes,Complexes, Histone Deacetylase,Deacetylase Complexes, Histone,Deacetylase, Histone,Deacetylases, Histone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006877 Hydroxamic Acids A class of weak acids with the general formula R-CONHOH. Hydroxamic Acid,Acid, Hydroxamic,Acids, Hydroxamic
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D056572 Histone Deacetylase Inhibitors Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains. HDAC Inhibitor,HDAC Inhibitors,Histone Deacetylase Inhibitor,Deacetylase Inhibitor, Histone,Deacetylase Inhibitors, Histone,Inhibitor, HDAC,Inhibitor, Histone Deacetylase,Inhibitors, HDAC,Inhibitors, Histone Deacetylase

Related Publications

Maurizio Taddei, and Elena Cini, and Luca Giannotti, and Giuseppe Giannini, and Gianfranco Battistuzzi, and Davide Vignola, and Loredana Vesci, and Walter Cabri
Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC).
October 2002, Bioorganic & medicinal chemistry letters,
Maurizio Taddei, and Elena Cini, and Luca Giannotti, and Giuseppe Giannini, and Gianfranco Battistuzzi, and Davide Vignola, and Loredana Vesci, and Walter Cabri
Amino hydroxamic acids as potent inhibitors of leukotriene A4 hydrolase.
October 1995, Bioorganic & medicinal chemistry,
Maurizio Taddei, and Elena Cini, and Luca Giannotti, and Giuseppe Giannini, and Gianfranco Battistuzzi, and Davide Vignola, and Loredana Vesci, and Walter Cabri
5-membered cyclic hydroxamic acids as HDAC inhibitors.
April 2015, Journal of enzyme inhibition and medicinal chemistry,
Maurizio Taddei, and Elena Cini, and Luca Giannotti, and Giuseppe Giannini, and Gianfranco Battistuzzi, and Davide Vignola, and Loredana Vesci, and Walter Cabri
Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors.
July 2007, Bioorganic & medicinal chemistry letters,
Maurizio Taddei, and Elena Cini, and Luca Giannotti, and Giuseppe Giannini, and Gianfranco Battistuzzi, and Davide Vignola, and Loredana Vesci, and Walter Cabri
Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
April 2011, Bioorganic & medicinal chemistry letters,
Maurizio Taddei, and Elena Cini, and Luca Giannotti, and Giuseppe Giannini, and Gianfranco Battistuzzi, and Davide Vignola, and Loredana Vesci, and Walter Cabri
Sulfonamide-based hydroxamic acids as potent inhibitors of mouse macrophage metalloelastase.
April 1998, Bioorganic & medicinal chemistry letters,
Maurizio Taddei, and Elena Cini, and Luca Giannotti, and Giuseppe Giannini, and Gianfranco Battistuzzi, and Davide Vignola, and Loredana Vesci, and Walter Cabri
Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
January 2011, Bioorganic & medicinal chemistry letters,
Maurizio Taddei, and Elena Cini, and Luca Giannotti, and Giuseppe Giannini, and Gianfranco Battistuzzi, and Davide Vignola, and Loredana Vesci, and Walter Cabri
Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors.
June 2015, Chemical communications (Cambridge, England),
Maurizio Taddei, and Elena Cini, and Luca Giannotti, and Giuseppe Giannini, and Gianfranco Battistuzzi, and Davide Vignola, and Loredana Vesci, and Walter Cabri
1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
April 2018, European journal of medicinal chemistry,
Maurizio Taddei, and Elena Cini, and Luca Giannotti, and Giuseppe Giannini, and Gianfranco Battistuzzi, and Davide Vignola, and Loredana Vesci, and Walter Cabri
Perfluorinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa.
April 2017, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!